Aurinia Pharmaceuticals Inc. (AUPH)

Profile

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical need. Aurinia Pharmaceuticals develops and commercializes LUPKYNIS, an oral treatment for adults with active lupus nephritis, a serious kidney complication associated with systemic lupus erythematosus. The company also advances pipeline programs such as aritinercept, a dual inhibitor targeting B cell-activating factor and proliferation-inducing ligand for potential autoimmune indications. Aurinia Pharmaceuticals serves patients and healthcare providers in markets including the United States and Japan, with its commercial and research activities centered on immune-mediated disease treatment. Based in Edmonton, Canada, the company operates as a specialist player in the autoimmune disease segment of the biopharmaceutical industry.